ETON
Eton Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth -18.2% ·
share flow +10.0% ·
net new positions -20.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 69 | +17 | 8.71M | $315.16M | +19 | −1 |
| Q1 2026 | 53 | 0 | 6.86M | $169.02M | +7 | −7 |
| Q4 2025 | 53 | +3 | 7.09M | $119.84M | +3 | — |
| Q3 2025 | 13 | +1 | 6.27M | $136.34M | +1 | — |
| Q2 2025 | 9 | -2 | 4.42M | $63.03M | +1 | −3 |
| Q1 2025 | 8 | +2 | 1.18M | $15.27M | +3 | −1 |
| Q4 2024 | 6 | +2 | 854.61K | $11.39M | +2 | — |
| Q3 2024 | 3 | -1 | 376.73K | $2.26M | +1 | −2 |
| Q2 2024 | 4 | — | 363.35K | $1.20M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 1.53M | — | $21.83M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 1.53M | — | $21.83M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 1.53M | — | $21.83M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 1.53M | — | $21.83M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 1.53M | — | $21.83M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | The Vanguard Group ✦ (passive) | 1.31M | — | $18.70M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | The Vanguard Group ✦ (passive) | 1.31M | — | $18.70M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | The Vanguard Group ✦ (passive) | 1.31M | — | $18.70M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 592.87K | +98.8% | $8.45M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 592.87K | +98.8% | $8.45M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 405.90K | +48.1% | $5.78M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | State Street Global Advisors ✦ (passive) | 323.19K | +182.9% | $4.61M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 214.55K | +160.5% | $3.06M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Wellington Management ✦ | 29.21K | +15.5% | $416,285 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 29.21K | +15.5% | $416,285 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Wellington Management ✦ | 29.21K | +15.5% | $416,285 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 12.84K | New | $183,000 | 0.0% | New | 1 | SEC ↗ |
| 18 | Fidelity (FMR) ✦ | 455 | — | $6,484 | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Fidelity (FMR) ✦ | 455 | — | $6,484 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $183,000 | 0.0% |
Exited
| Millennium Management | $4.62M | was 0.0% |
| Citadel Advisors | $317,906 | was 0.0% |
| Point72 Asset Management | $19,470 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 115 holders, 17.61M shares, $424.10M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 25.00K sh · $1.63M
Officer, Director · 47.31K sh · $2.85M
Officer, Director · 36.37K sh · $2.22M
Officer, Director · 7.34K sh · $456,085
Officer, Director · 8.98K sh · $562,472
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology